Liquidia Announces GDA Has Accepted For Review Co.'s amendment to Tentatively Approved NDA For YUTREPIA
Portfolio Pulse from Bill Haddad
Liquidia has announced that the Generic Drug Administration (GDA) has accepted for review the company's amendment to the Tentatively Approved New Drug Application (NDA) for YUTREPIA.
September 25, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The acceptance of Liquidia's amendment to the NDA for YUTREPIA by the GDA could potentially lead to the drug's approval, which would be a positive development for the company.
The acceptance of the amendment to the NDA for YUTREPIA by the GDA is a step towards the potential approval of the drug. If approved, this could increase Liquidia's revenues and positively impact its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100